Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

NCT02426229 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT02426229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02426229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Lead sponsor
Medical University of South Carolina
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2016
Completion date
June 21, 2018
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, scleroderma